Literature DB >> 7481575

The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias.

P Sachdev1.   

Abstract

This article examines the epidemiological data on chronic akathisia, tardive akathisia, and withdrawal akathisia. The limitations of the data are discussed--in particular, the lack of consistent definitions of the syndromes. The studies suggest that a significant proportion of patients chronically treated with neuroleptics suffer from akathisia. The prevalence may be as high as 40 percent, although a conservative estimate would be closer to 30 percent. Risk factors for the development of chronic akathisia and tardive akathisia are poorly understood, but old age, female sex, iron deficiency, negative symptoms, cognitive dysfunction, and affective disorder diagnosis need to be studied further for their potential role. While there is convincing evidence that akathisia may develop after neuroleptic cessation or reduction in dose, the prevalence and risk factors for withdrawal akathisia are not known. Reports of akathisia in children and the elderly have been few, and more systematic research is necessary. Akathisia appears to be common in individuals with mental retardation treated chronically with neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7481575     DOI: 10.1093/schbul/21.3.451

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  11 in total

1.  The syndrome of motor restlessness--a treatable but under-recognised disorder.

Authors:  A Bakheit
Journal:  Postgrad Med J       Date:  1997-09       Impact factor: 2.401

Review 2.  Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.

Authors:  M R Caligiuri; D V Jeste; J P Lacro
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 3.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

4.  Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Authors:  J Sloan Manning; Susan L McElroy
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

5.  Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.

Authors:  Bunta Yoshimura; Kojiro Sato; Shinji Sakamoto; Masaru Tsukahara; Yusaku Yoshimura; Ryuhei So
Journal:  Psychopharmacology (Berl)       Date:  2018-11-15       Impact factor: 4.530

6.  Delayed-onset akathisia due to amisulpride.

Authors:  Murad Atmaca; Sevda Korkmaz
Journal:  Indian J Pharmacol       Date:  2011-07       Impact factor: 1.200

7.  Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.

Authors:  Shaina Musco; Laura Ruekert; Jaclyn Myers; Dennis Anderson; Michael Welling; Elizabeth Ann Cunningham
Journal:  J Clin Psychopharmacol       Date:  2019 Jul/Aug       Impact factor: 3.153

8.  Risperidone-Induced Tardive Akathisia: A Rare Antipsychotic Side Effect with Management Issues.

Authors:  Biswa Ranjan Mishra; Rajeev Ranjan; Debadatta Mohapatra; Santanu Nath
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

9.  A survey of the tardive dyskinesia induced by antipsychotic drugs in patients with schizophrenia.

Authors:  Sahel Hemmati; Ali Nazeri Astaneh; Farin Solemani; Roshanak Vameghi; Firouzeh Sajedi; Naser Tabibi
Journal:  Iran J Psychiatry       Date:  2010

10.  Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family.

Authors:  Yolande Lucire; Christopher Crotty
Journal:  Pharmgenomics Pers Med       Date:  2011-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.